Castle biosciences presents new data demonstrating the impact of decisiondx®-scc test results on the management of medicare-eligible patients with cutaneous squamous cell carcinoma and one or more risk factors

Friendswood, texas--(business wire)---- $cstl #cstl--castle announced new data showing that decisiondx-scc test results positively impacted patient management in over 80% of a medicare-eligible cohort.
CSTL Ratings Summary
CSTL Quant Ranking